Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Terazosin hydrochloride
Drug ID BADD_D02159
Description Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate[A176837].
Indications and Usage Terazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertension[FDA Label].
Marketing Status approved
ATC Code G04CA03
DrugBank ID DB01162
KEGG ID D00610
MeSH ID C041226
PubChem ID 44383
TTD Drug ID D0P9RF
NDC Product Code 50090-2371; 51407-733; 51407-735; 53002-1726; 63629-2439; 71610-698; 65372-1127; 65862-205; 42291-820; 42291-822; 53002-1727; 63187-620; 66267-325; 71610-503; 71610-715; 50268-765; 50268-766; 53002-1728; 60760-316; 68788-9817; 71610-594; 71610-720; 50090-0657; 51407-734; 53002-1250; 68788-9816; 24689-792; 24689-961; 51407-732; 59746-384; 63629-5237; 71335-2125; 71610-595; 63415-0116; 49999-227; 50090-1559; 50268-764; 42291-823; 59746-386; 63187-456; 71610-478; 71610-510; 42291-821; 50268-767; 68788-9815; 70518-3114; 73435-029; 24689-855; 24689-882; 50090-2623; 55700-750; 59746-383; 59746-385
UNII D32S14F082
Synonyms Terazosin | Adecur | Apo-Terazosin | Dysalfa | Hytrin | Flotrin | Hytrin BPH | Hytrine | Heitrin | Deflox | Magnurol | Novo-Terazosin | Nu-Terazosin | PMS-Terazosin | terazosin hydrochloride anhydrous | Sutif | Tazusin | Terazoflo | Terazosin AZU | Terazosin Hexal | Terazosin hydrochloride | terazosin, monohydrochloride, dihydrate | Terazosina Alter | Terazosina Kern | Terazosina Qualix | Zayasel | A 45975 | ratio-Terazosin
Chemical Information
Molecular Formula C19H26ClN5O4
CAS Registry Number 63074-08-8
SMILES COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Amblyopia06.02.01.001--Not Available
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.002--
Back pain15.03.04.005--
Bronchitis22.07.01.001; 11.01.09.001--
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Cough22.02.03.001--
Depression19.15.01.001--
Diarrhoea07.02.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.11.04.006--
Dry mouth07.06.01.002--
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.004--
Epistaxis24.07.01.005; 22.04.03.001--
Face oedema08.01.07.003; 23.04.01.004; 10.01.05.002--
Fatigue08.01.01.002--
Flatulence07.01.04.002--
Gout14.09.01.001; 15.01.06.001--Not Available
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
The 1th Page    1 2 3    Next   Last    Total 3 Pages